NASDAQ:EMBC Embecta (EMBC) Stock Price, News & Analysis $10.66 +0.15 (+1.44%) As of 03:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Embecta Stock (NASDAQ:EMBC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Embecta alerts:Sign Up Key Stats Today's Range$10.33▼$10.7750-Day Range$10.51▼$13.6352-Week Range$10.27▼$21.48Volume561,098 shsAverage Volume461,244 shsMarket Capitalization$623.06 millionP/E Ratio10.69Dividend Yield5.63%Price Target$20.33Consensus RatingHold Company OverviewEmbecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.Read More… Embecta Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks84th Percentile Overall ScoreEMBC MarketRank™: Embecta scored higher than 84% of companies evaluated by MarketBeat, and ranked 164th out of 917 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingEmbecta has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageEmbecta has only been the subject of 1 research reports in the past 90 days.Read more about Embecta's stock forecast and price target. Earnings and Valuation3.8 / 5Proj. Earnings Growth7.72% Earnings GrowthEarnings for Embecta are expected to grow by 7.72% in the coming year, from $2.85 to $3.07 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Embecta is 10.69, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.81.Price to Earnings Ratio vs. SectorThe P/E ratio of Embecta is 10.69, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.76.Price to Earnings Growth RatioEmbecta has a PEG Ratio of 0.78. PEG Ratios below 1 indicate that a company could be undervalued.Read more about Embecta's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.49% of the float of Embecta has been sold short.Short Interest Ratio / Days to CoverEmbecta has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Embecta has recently increased by 30.09%, indicating that investor sentiment is decreasing significantly. Dividend3.3 / 5Dividend StrengthStrong Dividend LeadershipEmbecta is a leading dividend payer. It pays a dividend yield of 4.99%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthEmbecta does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Embecta is 66.67%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Embecta will have a dividend payout ratio of 19.54% next year. This indicates that Embecta will be able to sustain or increase its dividend.Read more about Embecta's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.49% of the float of Embecta has been sold short.Short Interest Ratio / Days to CoverEmbecta has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Embecta has recently increased by 30.09%, indicating that investor sentiment is decreasing significantly. News and Social Media3.4 / 5News Sentiment1.03 News SentimentEmbecta has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Embecta this week, compared to 4 articles on an average week.Search Interest2 people have searched for EMBC on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Embecta insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.42% of the stock of Embecta is held by insiders.Percentage Held by Institutions93.83% of the stock of Embecta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Embecta's insider trading history. Receive EMBC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Embecta and its competitors with MarketBeat's FREE daily newsletter. Email Address EMBC Stock News Headlinesembecta to Showcase Phased Approach for Value Creation and Present Long Range Financial Plan at 2025 Analyst and Investor DayMay 22 at 6:30 AM | globenewswire.comEmbecta: Not Nearly As Cheap As The 4x Forward P/E Ratio Would ImplyMay 15, 2025 | seekingalpha.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.May 23, 2025 | Paradigm Press (Ad)BrainsWay (NASDAQ:BWAY) & Embecta (NASDAQ:EMBC) Head to Head AnalysisMay 13, 2025 | americanbankingnews.comEmbecta Corp. (NASDAQ:EMBC) Q2 2025 Earnings Call TranscriptMay 10, 2025 | msn.comEmbecta Corp (EMBC) Q2 2025 Earnings Call Highlights: Strategic Growth Amid Revenue DeclineMay 10, 2025 | finance.yahoo.comEmbecta raises adjusted EBITDA margin outlook for FY 2025 amid restructuring and debt reductionMay 10, 2025 | msn.comEMBECTA Earnings Preview: Recent $EMBC Insider Trading, Hedge Fund Activity, and MoreMay 9, 2025 | nasdaq.comSee More Headlines EMBC Stock Analysis - Frequently Asked Questions How have EMBC shares performed this year? Embecta's stock was trading at $20.65 at the beginning of the year. Since then, EMBC stock has decreased by 48.4% and is now trading at $10.6610. View the best growth stocks for 2025 here. How were Embecta's earnings last quarter? Embecta Corp. (NASDAQ:EMBC) issued its earnings results on Friday, May, 9th. The company reported $0.70 EPS for the quarter, topping analysts' consensus estimates of $0.66 by $0.04. The firm's quarterly revenue was down 9.8% on a year-over-year basis. Read the conference call transcript. Who are Embecta's major shareholders? Top institutional shareholders of Embecta include Vanguard Group Inc. (11.59%), American Century Companies Inc. (6.56%), Yacktman Asset Management LP (4.05%) and Millennium Management LLC (1.52%). Insiders that own company stock include Devdatt Kurdikar, Jacob Elguicze, Jeffrey Z Mann, David F Melcher and Milton Mayo Morris. View institutional ownership trends. How do I buy shares of Embecta? Shares of EMBC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Embecta own? Based on aggregate information from My MarketBeat watchlists, some other companies that Embecta investors own include Waste Connections (WCN), AUO (AUOTY), The RMR Group (RMR), DiamondRock Hospitality (DRH), American Water Works (AWK), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM). Company Calendar Record date for 3/14 Dividend2/28/2025Ex-Dividend for 3/14 Dividend2/28/2025Dividend Payable3/14/2025Last Earnings5/09/2025Today5/23/2025Record date for 6/13 Dividend5/28/2025Ex-Dividend for 6/13 Dividend5/28/2025Dividend Payable6/13/2025Next Earnings (Estimated)8/08/2025Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:EMBC CIK1872789 Webwww.embecta.com Phone201-847-6880FaxN/AEmployees1,900Year FoundedN/APrice Target and Rating Average Stock Price Target$20.33 High Stock Price Target$26.00 Low Stock Price Target$15.00 Potential Upside/Downside+93.5%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$0.90 Trailing P/E Ratio10.51 Forward P/E Ratio3.69 P/E Growth0.78Net Income$78.30 million Net Margins5.25% Pretax Margin2.64% Return on Equity-19.22% Return on Assets11.92% Debt Debt-to-Equity RatioN/A Current Ratio2.24 Quick Ratio1.67 Sales & Book Value Annual Sales$1.08 billion Price / Sales0.57 Cash Flow$2.43 per share Price / Cash Flow4.32 Book Value($13.23) per share Price / Book-0.79Miscellaneous Outstanding Shares58,443,000Free Float57,890,000Market Cap$614.24 million OptionableOptionable Beta1.24 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:EMBC) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Embecta Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Embecta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.